dc.contributor.advisor | Mollenhauer, Brit Prof. Dr. | de |
dc.contributor.author | Werner, Stefanie | de |
dc.date.accessioned | 2013-01-14T15:34:24Z | de |
dc.date.available | 2013-12-05T23:50:05Z | |
dc.date.issued | 2012-11-16 | de |
dc.identifier.uri | http://hdl.handle.net/11858/00-1735-0000-000D-F02E-5 | de |
dc.identifier.uri | http://dx.doi.org/10.53846/goediss-1646 | |
dc.format.mimetype | application/pdf | de |
dc.language.iso | ger | de |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/ | de |
dc.title | DeNoPa Kassel: Die prospektive Langzeit-Follow-up-Studie zu Biomarkern und nicht-motorischen Symptomen bei Morbus Parkinson - Pilotstudie baseline | de |
dc.type | doctoralThesis | de |
dc.title.translated | DeNoPa Kassel: The prospective long-term follow-up study on biomarkers and non-motor symptoms for Parkinson's disease - pilot study baseline | de |
dc.contributor.referee | Mollenhauer, Brit Prof. Dr. | de |
dc.date.examination | 2012-12-11 | de |
dc.subject.dnb | 610 Medizin, Gesundheit | de |
dc.subject.gok | MED 532 | de |
dc.description.abstracteng | To date there are no accepted and
sufficient validated biomarkers for Parkinson's disease (PD).
Diagnosis is exclusively based on motor symptoms and the response
on dopaminergic medication. Misdiagnoses are common especially in
early stages of disease. In view of future neuroprotective therapy
early diagnosis or if possible the identification of individuals at
risk in presymptomatic stages is very desirable. The present pilot
study of the DeNoPa („De-Novo Parkinson“) study deals with non
motor symptoms in de-novo PD as well as with potential diagnostic
biomarkers and the feasibility of the main study. For this purpose
the baseline data of the participants recruited in the first seven
month of the study (30 patients plus 10 healthy controls) have been
evaluated. The analysis on feasibility of DeNoPa study showed that
the targeted recruitment numbers are realistically achievable. Also
the implementation of the planned investigations proved feasible.
The pilot study showed that non-motor symptoms play an important
role already at the onset of the disease: Screening with Non-Motor
Symptoms Questionnaire and Scale resulted in a significant
difference between patients and controls. In addition we could
detect a significant influence of the disease on quality of life in
patients by using Parkinson's Disease Questionnaire. Olfactory
testing with “sniffin' sticks | de |
dc.contributor.coReferee | Sommer, Martin Prof. Dr. | de |
dc.subject.topic | Medicine | de |
dc.subject.ger | M. Parkinson; Biomarker; nicht-motorische Symptome; Frühdiagnose; DeNoPa-Studie; Riechtest; REM-Schlaf-Verhaltensstörung; Hirnparenchymsonographie | de |
dc.subject.eng | Parkinson's disease; biomarkers; non-motor symptoms; early diagnosis; DeNoPa study; olfactory testing; REM-sleep behavior disorder; trancranial sonography | de |
dc.subject.bk | 44.90 | de |
dc.identifier.urn | urn:nbn:de:gbv:7-webdoc-3794-4 | de |
dc.identifier.purl | webdoc-3794 | de |
dc.affiliation.institute | Medizinische Fakultät | de |
dc.description.embargoed | 2013-12-05 | de |
dc.identifier.ppn | 774032200 | |